Beauty

Shiseido to sell Aupres-maker SLC to IDG-led consortium

The binding agreement covers Shiseido’s Chinese subsidiary and the Aupres brand, with closing expected between late 2026 and early 2027 pending regulatory approvals.

Ingrid LindqvistNovember 19, 20265 min read3 views
A cosmetic bottle and cream jar sit beside abstract factory and contract forms, with a translucent handover path linking two corporate structures in a cool-toned studio setting.

Shiseido has signed a binding agreement to sell its entire Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The financial terms of the transaction were not disclosed.

The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. The sale is part of Shiseido’s push to improve profitability and capital efficiency under its 2030 Medium-Term Strategy.

Focus on priority brands

Shiseido says the strategy aims to drive sustainable growth and strengthen its competitiveness in China by focusing management resources on areas where it “enjoys the greatest competitive advantage.” The company describes the divestment as a way to shed a business that needs continued investment in product innovation and digital capabilities, allowing the group to concentrate on priority brands and higher-growth opportunities.

China remains a strategically important market for Shiseido, according to the company. It describes the market as attractive and dynamic, with a competitive landscape evolving amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.

Joint-venture background

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. SLC has sold the C-beauty brand Aupres since 1994. With the current joint-venture agreement set to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership ahead of the sale.

Under the transaction, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC’s new management team will hold the remaining 5%. The deal includes SLC’s Beijing factory and production equipment. Shiseido says it believes independent operation under IDG will support SLC’s sustainable growth and brand value.

Transition support and results

To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The company says the collaboration is intended to maintain SLC’s innovation capabilities, product quality and business continuity.

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion, or about US$422.13 million. The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion, or about US$433 million, to ¥87 billion, or about US$546 million, on the back of those results.